Pharmacokinetics study of combined treatment lapatinib and tamoxifen in advanced/metastatic breast cancer.

Trial Profile

Pharmacokinetics study of combined treatment lapatinib and tamoxifen in advanced/metastatic breast cancer.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2013

At a glance

  • Drugs Lapatinib (Primary) ; Tamoxifen (Primary)
  • Indications Advanced breast cancer
  • Focus Pharmacokinetics
  • Acronyms LAPATAM
  • Most Recent Events

    • 12 Oct 2009 Interim results for the first six evaluable patients presented at 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.
    • 11 Feb 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 11 Dec 2008 Preliminary results from 6 patients were reported in an abstract, and final pharmacokinetic analyses (from 23 patients) were presented at the 31st Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top